Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 May 16
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
ABSTRACT
What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.
Related Questions
Does PSADT play a factor in your decision-making? If so, how specifically?
I've tended to wait until the PSA is 10-15, re-image, and then begin...
New comment by Radiation Oncologist at University Hospital Basel ( January 20, 2025)
Very good answer, thank you! Just one more comment on EMBARK.
The NEJM paper states:
Patients were excluded if they showed evidence of distant metastatic disease on conventi...